MedTrace Logo

Metabolic Features Effects on FAST Score in MASLD Patients

NCT06867419 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 385

Last updated 2025-03-10

No results posted yet for this study

Summary

The goal of this observational cross-sectional study is to evaluate the effect of metabolic features on Fibroscan-AST (FAST) score stratification in metabolic dysfunction-associated steatotic liver disease (MASLD) patients in Egypt.

Researchers will identify the metabolic risk factors in patients with MASLD. evaluate the effect of metabolic features on stratifying MASLD patients by predicting higher FAST score.

Participants will be subjected to history taking, clinical examination, laboratory investigations, abdominal ultrasonography, and transient elastography (Fibroscan) to measure liver stiffness (LSM) and controlled attenuation parameter (CAP). The Non-alcoholic fatty liver disease (NAFLD) fibrosis score and FAST score will be calculated.

Conditions

  • Metabolic Dysfunction-Associated Steatotic Liver Disease

Interventions

RADIATION

Transient Elastography

participants will be subjected to anthropometric measurements, laboratory investigations (complete blood count, liver and kidney functions, lipid profile, virology tests, fasting insulin, fasting sugar, 2 hour postprandial sugar, HbA1c, and HOMA-IR), radiological examination (abdominal ultrasound, Fibroscan). the NAFLD fibrosis score, APRI, FIB-4 score, and FAST score will be calculated.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Rania M Elkafoury, MD · Tropical medicine and infectious diseases Department, Faculty of Medicine, Tanta University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2025-03-30
Completion
2025-03-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06867419 on ClinicalTrials.gov